Our study was based on a randomized, double-blind, multicenter Phase IB/III trial evaluating SHR-1316 (anti-PD-L1) with platinum chemotherapy versus placebo with platinum chemotherapy in resectable Stage II/III non-small cell lung cancer, focusing on efficacy and safety. This evidence concerns the gene CD274 and non-small cell lung carcinoma.